ArticleScientific reports2017
Evaluation of Acridine Orange Derivatives as DNA-Targeted Radiopharmaceuticals for Auger Therapy: Influence of the Radionuclide and Distance to DNA.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 70 citations in OpenAlex.
- Rational design of an acridine-derived click chemistry-based artificial metallo-nuclease.RSC chemical biology · 2026Article
- Industrial Hydrocarbons Exposure Deteriorates Sperm Integrity and Reproductive Function.Journal of biochemical and molecular toxicology · 2026Article
- Taming unconventional nucleic acid structures: synthesis of acridine- and 1,10-phenanthroline-based G-quadruplex binders.RSC advances · 2026Review
- Auger-Emitting Radionuclides in Radiopharmaceutical Research: Decay-Associated Processes, Vector-Dependent Localization, and Translational Perspectives.International journal of molecular sciences · 2026Review
- Article
- Marshalling the Potential of Auger Electron Radiopharmaceutical Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Review
- DNA Repair Inhibitors: Potential Targets and Partners for Targeted Radionuclide Therapy.Pharmaceutics · 2023Review
- A systematic computational study of acridine derivatives through conceptual density functional theory.Molecular diversity · 2023Article
- Assessment of Aptamer as a Potential Drug Targeted Delivery for Retinal Angiogenesis Inhibition.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Molluscicidal and Larvicidal Potency ofPharmaceutics · 2023Article
- Phototoxic Potential of Different DNA Intercalators for Skin Cancer Therapy: In Vitro Screening.International journal of molecular sciences · 2023Article
- Cellular lethal damage ofFrontiers in medicine · 2023Article
- Advancements in the use of Auger electrons in science and medicine during the period 2015-2019.International journal of radiation biology · 2023Review
- Radiopharmaceuticals heat anti-tumor immunity.Theranostics · 2023Review
- Gallic Acid-Triethylene Glycol Aptadendrimers Synthesis, Biophysical Characterization and Cellular Evaluation.Pharmaceutics · 2022Article
- Searching for a Paradigm Shift in Auger-Electron Cancer Therapy with Tumor-Specific Radiopeptides Targeting the Mitochondria and/or the Cell Nucleus.International journal of molecular sciences · 2022Article
- Development of NovelJournal of medicinal chemistry · 2022Article
- Ligands as Stabilizers of G-Quadruplexes in Non-Coding RNAs.Molecules (Basel, Switzerland) · 2021Review
- Aptamer-Functionalized Gold Nanoparticles for Drug Delivery to Gynecological Carcinoma Cells.Cancers · 2021Article
- Metal-Based G-Quadruplex Binders for Cancer Theranostics.Pharmaceuticals (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A new family of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.